Omeros (NASDAQ:OMER) Downgraded by StockNews.com to Sell

Omeros (NASDAQ:OMER) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Friday.

Several other equities analysts have also commented on OMER. Needham & Company LLC restated a “hold” rating on shares of Omeros in a report on Friday, January 17th. D. Boral Capital restated a “buy” rating and set a $36.00 price target on shares of Omeros in a research note on Thursday, February 20th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Omeros Price Performance

OMER opened at $9.10 on Friday. The company’s 50 day simple moving average is $8.70 and its two-hundred day simple moving average is $7.28. Omeros has a 1-year low of $2.61 and a 1-year high of $13.60. The firm has a market capitalization of $527.35 million, a price-to-earnings ratio of -3.94 and a beta of 2.03.

Institutional Investors Weigh In On Omeros

Several large investors have recently added to or reduced their stakes in OMER. Truvestments Capital LLC boosted its position in Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 1,669 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of Omeros by 79.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 1,972 shares in the last quarter. Quantbot Technologies LP purchased a new position in Omeros in the fourth quarter valued at $46,000. BNP Paribas Financial Markets grew its stake in Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 7,016 shares in the last quarter. Finally, Picton Mahoney Asset Management increased its holdings in Omeros by 692.5% during the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 4,404 shares during the period. 48.79% of the stock is owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.